208 related articles for article (PubMed ID: 26775883)
1. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Kantarjian HM; Lioure B; Kim SK; Atallah E; Leguay T; Kelly K; Marolleau JP; Escoffre-Barbe M; Thomas XG; Cortes J; Jabbour E; O'Brien S; Bories P; Oprea C; Hatteville L; Dombret H
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):139-45. PubMed ID: 26775883
[TBL] [Abstract][Full Text] [Related]
2. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
Trnĕný M; Verhoef G; Dyer MJ; Ben Yehuda D; Patti C; Canales M; Lopez A; Awan FT; Montgomery PG; Janikova A; Barbui AM; Sulek K; Terol MJ; Radford J; Guidetti A; Di Nicola M; Siraudin L; Hatteville L; Schwab S; Oprea C; Gianni AM
Haematologica; 2018 Aug; 103(8):1351-1358. PubMed ID: 29748443
[TBL] [Abstract][Full Text] [Related]
3. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B; Thieblemont C; de Guibert S; Dupuis J; Ribrag V; Bouabdallah R; Morschhauser F; Navarro R; Le Gouill S; Haioun C; Houot R; Casasnovas O; Holte H; Lamy T; Broussais F; Payrard S; Hatteville L; Tilly H
Br J Haematol; 2016 Jun; 173(5):722-30. PubMed ID: 27010483
[TBL] [Abstract][Full Text] [Related]
4. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
5. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
6. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
[TBL] [Abstract][Full Text] [Related]
7. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Younes A; Kim S; Romaguera J; Copeland A; Farial Sde C; Kwak LW; Fayad L; Hagemeister F; Fanale M; Neelapu S; Lambert JM; Morariu-Zamfir R; Payrard S; Gordon LI
J Clin Oncol; 2012 Aug; 30(22):2776-82. PubMed ID: 22753910
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
[TBL] [Abstract][Full Text] [Related]
9. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F; Haeder T; Wartenberg-Demand A; Anderson KC
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):372-380. PubMed ID: 30930134
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
Beeram M; Krop IE; Burris HA; Girish SR; Yu W; Lu MW; Holden SN; Modi S
Cancer; 2012 Dec; 118(23):5733-40. PubMed ID: 22648179
[TBL] [Abstract][Full Text] [Related]
13. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; Rossi D; Stussi G; Zucca E; Stathis A; Sloss CM; Bertoni F
Haematologica; 2019 Aug; 104(8):1633-1639. PubMed ID: 30733273
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
[TBL] [Abstract][Full Text] [Related]
15. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
17. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
[TBL] [Abstract][Full Text] [Related]
19. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.
Gorin NC; Isnard F; Garderet L; Ikhlef S; Corm S; Quesnel B; Legrand O; Cachanado M; Rousseau A; Laporte JP
Eur J Haematol; 2013 Oct; 91(4):315-21. PubMed ID: 23738686
[TBL] [Abstract][Full Text] [Related]
20. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P; Eugene T; Robillard N; Isnard F; Nicolini F; Escoffre-Barbe M; Huguet F; Hunault M; Marcais A; Gaschet J; Cherel M; Guillaume T; Delaunay J; Peterlin P; Eveillard M; Thomas X; Ifrah N; Lapusan S; Bodet-Milin C; Barbet J; Faivre-Chauvet A; Ferrer L; Bene MC; Le Houerou C; Goldenberg DM; Wegener WA; Kraeber-Bodéré F
Lancet Haematol; 2015 Mar; 2(3):e108-17. PubMed ID: 26687796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
